Literature DB >> 12755956

Functional studies of the MEN1 gene.

S C Chandrasekharappa1, B T Teh.   

Abstract

Multiple endocrine neoplasia type 1 is an autosomal dominant cancer syndrome affecting primarily parathyroid, enteropancreatic endocrine and pituitary tissues. The inactivating germline and somatic mutations spread throughout the gene and the accompanying loss of the second allele in tumours show that the MEN1 gene is a tumour suppressor. The MEN1-encoded protein, menin, is a novel nuclear protein. Menin binds and alters JunD-, NF-kappaB-, Smad3-mediated transcriptional activation. The mouse Men1 knockout model mimicks the human MEN1 condition contributing to the understanding of tumorigenesis in MEN1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12755956     DOI: 10.1046/j.1365-2796.2003.01165.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  24 in total

1.  DNA hypermethylation profiles in squamous cell carcinoma of the vulva.

Authors:  Josena K Stephen; Kang Mei Chen; Misa Raitanen; Seija Grénman; Maria J Worsham
Journal:  Int J Gynecol Pathol       Date:  2009-01       Impact factor: 2.762

2.  The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression.

Authors:  Ya-Xiong Chen; Jizhou Yan; Karen Keeshan; Anthony T Tubbs; Haoren Wang; Albert Silva; Eric J Brown; Jay L Hess; Warren S Pear; Xianxin Hua
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-13       Impact factor: 11.205

3.  A case of multiple endocrine neoplasia type 1 combined with papillary thyroid carcinoma.

Authors:  Hai-Jin Kim; Jong-Suk Park; Chul-Sik Kim; Eun-Seok Kang; Bong-Soo Cha; Sung-Kil Lim; Kyung-Rae Kim; Hyun-Chul Lee; Chul-Woo Ahn
Journal:  Yonsei Med J       Date:  2008-06-30       Impact factor: 2.759

4.  Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family.

Authors:  Sandra Mastroianno; Massimo Torlontano; Alfredo Scillitani; Leonardo D'Aloiso; Antonella Verrienti; Nazario Bonfitto; Antonio De Bonis; Leonardo D'Agruma; Lucia Anna Muscarella; Vito Guarnieri; Franca Dicembrino; Marianna Maranghi; Cosimo Durante; Sebastiano Filetti
Journal:  Endocrine       Date:  2011-06-17       Impact factor: 3.633

5.  Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma.

Authors:  Katarzyna Kempinska; Bhavna Malik; Dmitry Borkin; Szymon Klossowski; Shirish Shukla; Hongzhi Miao; Jingya Wang; Tomasz Cierpicki; Jolanta Grembecka
Journal:  Mol Cancer Ther       Date:  2017-11-15       Impact factor: 6.261

6.  Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism.

Authors:  Viive M Howell; John W Cardinal; Anne-Louise Richardson; Oliver Gimm; Bruce G Robinson; Deborah J Marsh
Journal:  J Mol Diagn       Date:  2006-11       Impact factor: 5.568

7.  Menin induces apoptosis in murine embryonic fibroblasts.

Authors:  Robert W Schnepp; Hua Mao; Stephen M Sykes; Wei-Xing Zong; Albert Silva; Ping La; Xianxin Hua
Journal:  J Biol Chem       Date:  2003-12-18       Impact factor: 5.157

8.  Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.

Authors:  Akihiko Yokoyama; Zhong Wang; Joanna Wysocka; Mrinmoy Sanyal; Deborah J Aufiero; Issay Kitabayashi; Winship Herr; Michael L Cleary
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

9.  In vitro hematopoietic differentiation of mouse embryonic stem cells requires the tumor suppressor menin and is mediated by Hoxa9.

Authors:  Elizabeth Novotny; Sheila Compton; P Paul Liu; Francis S Collins; Settara C Chandrasekharappa
Journal:  Mech Dev       Date:  2009-04-22       Impact factor: 1.882

Review 10.  Cancer stem cells and the ontogeny of lung cancer.

Authors:  Craig D Peacock; D Neil Watkins
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.